Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
21 hedge funds and large institutions have $5.17M invested in Ocera Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.
3.33% less ownership
Funds ownership: 20.45% → 17.12% (-3.3%)
13% less funds holding
Funds holding: 24 → 21 (-3)
18% less capital invested
Capital invested by funds: $6.29M → $5.17M (-$1.12M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$322K |
| 2 |
DMK
David M. Knott
|
+$42.7K |
| 3 |
VF
Virtu Financial
New York
|
+$15.3K |
| 4 |
AWS
AJ Wealth Strategies
New York
|
+$11.3K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$214 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
-$794K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$140K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$60.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.5K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$36.8K |
OCRX Hedge Fund Activity: Q3 2017 in Review
21 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q3 2017, worth a combined $5.17M — down 18% from $6.29M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of OCRX and 2 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Hikari Power, adding an estimated $322K. The largest seller was VHCP Management II, cutting an estimated $794K.
- 21 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q3 2017, down from 24 in Q2 2017.
- Funds reported $5.17M of Ocera Therapeutics, Inc. stock for Q3 2017, down 18% quarter-over-quarter.
- 2 funds opened new Ocera Therapeutics, Inc. positions in Q3 2017 and 4 closed out, a net change of -2 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q3 2017 was Hikari Power, an estimated $322K added.
- The largest Ocera Therapeutics, Inc. seller in Q3 2017 was VHCP Management II, an estimated $794K sold.
Based on aggregated 13F filings for Q3 2017.